Michal Podrazil
Prague, PR, Czech Republic
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
Peripheral gene signatures reveal distinct cancer patient immunotypes with therapeutic implications for autologous DC-based vaccines.
Journal: Oncoimmunology
Published: July 28, 2022
Effectiveness and Durability of mRNA Vaccine-Induced SARS-CoV-2-Specific Humoral and Cellular Immunity in Severe Asthma Patients on Biological Therapy.
Journal: Frontiers in immunology
Published: March 08, 2022
The WNT/β-catenin signaling inhibitor XAV939 enhances the elimination of LNCaP and PC-3 prostate cancer cells by prostate cancer patient lymphocytes in vitro.
Journal: Scientific reports
Published: November 28, 2018
Personalized ex vivo multiple peptide enrichment and detection of T cells reactive to multiple tumor-associated antigens in prostate cancer patients.
Journal: Medical oncology (Northwood, London, England)
Published: August 11, 2017
Phase I/II trial of dendritic cell-based active cellular immunotherapy with DCVAC/PCa in patients with rising PSA after primary prostatectomy or salvage radiotherapy for the treatment of prostate cancer.
Journal: Cancer immunology, immunotherapy : CII
Published: February 23, 2017
Phase I/II clinical trial of dendritic-cell based immunotherapy (DCVAC/PCa) combined with chemotherapy in patients with metastatic, castration-resistant prostate cancer.
Journal: Oncotarget
Published: February 10, 2015
Active cellular immunotherapy of ovarian cancer using dendritic cells
Journal: Ceska gynekologie
Published: July 12, 2012
Showing 1-8 of 8
Last Updated: 09/26/2026